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Abstract All living organisms have systems for arsenic detox-
i¢cation. The common themes are (a) uptake of As(V) in the
form of arsenate by phosphate transporters, (b) uptake of
As(III) in the form of arsenite by aquaglyceroporins, (c) reduc-
tion of As(V) to As(III) by arsenate reductases, and (d) extru-
sion or sequestration of As(III). While the overall schemes for
arsenic resistance are similar in prokaryotes and eukaryotes,
some of the speci¢c proteins are the products of separate evolu-
tionary pathways. $ 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
This review will focus on selected mechanisms of arsenic
detoxi¢cation in prokaryotes and eukaryotes. Arsenic is a
semi-metal or metalloid with two biologically important oxi-
dation states, As(V) and As(III), as the oxyacids arsenic acid
(H3AsO4) or arsenous acid, also called arsenic trioxide
(As2O3). In solution at neutral pH, arsenic acid exists as the
arsenate oxyanion. The pKa of arsenous acid is 9.2, so that, at
neutral pH, it would be primarily present in solution as neu-
tral As(OH)3. As described below, this di¡erence in pKa is
relevant for the type of transport system that catalyzes uptake
of the pentavalent and trivalent forms of arsenic. The other
aspect of arsenic chemistry relevant to biological activity is
reactivity of As(III) as a soft metal ion, forming strong bonds
with functional groups such as the thiolates of cysteine resi-
dues and the imidazolium nitrogens of histidine residues.
Arsenic enters the biosphere primarily by leaching from
geological formations [1]. For example, in Michigan, arsenic
leaches into water from the Marshall Sandstone and Cold-
water Shale. Anthropomorphic sources include arsenical-con-
taining fungicides, pesticides and herbicides. The health e¡ects
of environmental arsenic can be devastating, and, over a peri-
od of decades, can progress to various forms of cancer. Its
ubiquity in the environment has led to the evolution of arsenic
defense mechanisms in every organism studied, from Escheri-
chia coli to man [2] (Fig. 1). As described below, organisms
take up As(V) via phosphate transporters [3,4] and As(III) by
aguaglyceroporins [5^7]. As(V) is reduced to As(III) [8,9],
which is either extruded from cells or sequestered in intra-
cellular compartments, either as free arsenite or as conjugates
with GSH or other thiols [10,11]. In addition, arsenic can be
methylated [12], although this process may increase arsenic
toxicity rather than contributing toward detoxi¢cation [13].
2. Arsenic uptake systems
In the prokaryote E. coli there are two phosphate trans-
porters, Pit and Pst [4]. Both catalyze arsenate uptake, but
the Pit system appears to be the predominant system for ar-
senate [14]. Similarly, in the eukaryote Saccharomyces cerevi-
siae several phosphate transporters participate in arsenate up-
take [3,15]. It can be assumed that arsenate is taken up
similarly in mammals, although this has not been demon-
strated.
Pathways for arsenite uptake into cells have only recently
been discovered. We ¢rst identi¢ed a trivalent metalloid trans-
porter as GlpF, the glycerol facilitator of E. coli [5]. A screen
of a random mutagenesis library turned up a mutant resistant
to Sb(III). The chemical properties of Sb(III) and As(III) are
very close, which makes it likely that GlpF is also an As(III)
transporter even though the cells did not exhibit increased
arsenite resistance. GlpF is an aquaglyceroporin, a member
of the aquaporin superfamily (Fig. 2A). Aquaglyceroporins
are multifunctional channels that transport neutral organic
solutes such as glycerol and urea [16]. Fps1p, the yeast homo-
log of GlpF, was recently shown to be the route of uptake of
arsenite in S. cerevisiae [6]. In that study the FPS1 gene was
targeted for deletion speci¢cally to examine its role in arsenite
resistance.
More recently we have shown that mammalian aquaglycer-
oporins catalyze uptake of trivalent metalloids [7]. We had
previously constructed a strain of S. cerevisiae with deletions
in the genes for in the two arsenite extrusion transporters,
Acr3p and Ycf1p [10], as described below. A strain with dis-
ruptions of both ACR3 and YCF1 was hypersensitive to ar-
senite. We next constructed the triple deletion of ACR3,
YCF1 and FPS1. This strain was unable to take up arsenite,
which resulted in arsenite resistance. To examine the arsenite
transport properties of mammalian aquaglyceroporins, we
cloned the genes for the rat AQP9 and mouse AQP7 into a
yeast vector and tested their ability to complement the arse-
nite-resistant phenotype of the triple yeast mutant. AQP9 was
expressed well and restored arsenite sensitivity. Cells express-
ing AQP9 transported both 73As(III) and 125Sb(III), thus
demonstrating that this protein can transport metalloids.
AQP7 was not expressed in yeast. However, when either
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AQP7 or AQP9 cRNA was microinjected into Xenopus laevis
oocytes, increased transport of 73As(III) was observed [7]. We
have recently expressed human AQP3, AQP9 and AQP10 in
yeast and found that only hAQP9 complemented the arsenite
phenotype, suggesting that only some aquaglyceroporins
transport As(III) (Z. Liu and B.R., unpublished). What chem-
ical species of As(III) do the aquaglyceroporins recognize?
With a pKa of 9.2, As(OH)3 would predominate in solution
at neutral pH. Since AQP7 and AQP9 conduct transmem-
brane movement of neutral species, As(OH)3, which might
be considered an inorganic equivalent of glycerol, is the likely
substrate. This ¢nding may have relevance to human health
and disease. On the one hand, considerable individual vari-
ability in sensitivity to arsenic in drinking water has been
observed in countries such as India and Bangladesh [17]. It
is possible that this variability is due in part to di¡erent levels
of expression of aquaglyceroporins in those individuals. On
the other hand, arsenite is an e¡ective cancer chemotherapeu-
tic agent. Its anhydrous form, arsenic trioxide (Trisenox) has
been approved as a chemotherapeutic agent for the treatment
of acute promyelocytic leukemia [18,19]. Di¡erences in expres-
sion of AQP7 or AQP9 could lead to variability in response to
drug therapy in di¡erent patients.
3. Arsenate reductases
When the pentavalent oxyanion arsenate is taken up, it is
reduced to As(III) prior to extrusion or sequestration. Three
independently evolved families of arsenate reductase enzymes
have been recognized [20] (Fig. 2B). We reported the ¢rst
sequence of an arsenate reductase as the product of the last
gene of the ars operon of E. coli plasmid R773 [21]. Homo-
logues of this arsC gene are found in many bacteria, both on
plasmids and in chromosomes [1]. The crystal structure of the
16 kDa R773 ArsC has been reported with bound substrate
(arsenate) and product (arsenite) [22]. In the reaction cycle,
arsenate ¢rst binds to the anion site that is consists of three
basic residues, Arg60, Arg94 and Arg107. Phosphate and sul-
fate are competitive for binding at this site. In the next step
arsenate (but not phosphate or sulfate) forms a covalent ar-
senate thioester intermediate with the active site Cys12. It is
then reduced in two steps by glutaredoxin and glutathione,
producing the Cys12-S-As(III) intermediate, which hydrolyzes
to release arsenite. E. coli has three glutaredoxins, Grx1, Grx2
and Grx3, any one of which will serve as source of reducing
potential for arsenate reduction, although Grx2 is preferred
[23].
A second family of arsenate reductases also widely distrib-
uted in bacteria is typi¢ed by the arsC gene product of Staph-
ylococcus aureus plasmid pI258 [8]. It is unfortunate that this
enzyme is also called ArsC considering that it is unrelated to
the ¢rst family of arsenate reductases. The pI258 enzyme uses
thioredoxin as the source of reducing potential [24] and has
two intramolecular cysteine residues that participate in the
catalytic cycle [25]. The crystal structures of the pI258 ArsC
and its homolog from Bacillus subtilis have recently been re-
ported [26,27]. Interestingly, this enzyme is related to low-
molecular-weight protein tyrosine phosphate phosphatases
and exhibits low-level phosphatase activity [26].
The third family of arsenate reductases is also related to
protein tyrosine phosphate phosphatases, although to a di¡er-
ent family of phosphatases than the pI258 ArsC. The only
member of the family to be characterized to date is Acr2p
from S. cerevisiae [28,29]. It is related to the superfamily of
protein phosphatases that includes CDC25a, a cell cycle phos-
phatase [30] and uses a similar HisCys(X)5Arg motif in its
active site [31].
Like the R773 ArsC, Acr2p has a single active site cysteine
residue and uses glutaredoxin and glutathione as reductants
[32]. Even though it is not related to either of the bacterial
ArsC arsenate reductases, it can be heterologously expressed
in E. coli and complements an arsC deletion. It does not
exhibit phosphatase activity. However, we have constructed
an Acr2p mutant that has gained phosphatase activity and
lost arsenate reductase activity (R. Mukhopadhyay and
B.R., unpublished). The ease by which a reductase can be
changed into a phosphatase has led us to propose that, under
the selective pressure of ubiquitous arsenate in the environ-
ment, arsenate reductases evolved from phosphatases.
So far no mammalian members of any of the three families
of arsenate reductases has been identi¢ed. It should be
pointed out, however, that the relatedness of Acr2p to the
widespread protein tyrosine phosphatase family makes it dif-
¢cult to identify homologs with arsenate reductase activity
through a genomics approach. Arsenate reductase activity
has been observed in vitro in extracts from human liver
[33]. Recently the activity has been attributed to the enzyme
purine nucleotide phosphorylase [34]. Whether this enzyme
functions in vivo in arsenic detoxi¢cation has not yet been
examined.
Cytosolic arsenite, whether as the product of arsenate re-
ductase or from uptake via an aquaglyceroporin, is detoxi¢ed
by removal from the cytosol [1,35]. It is rather counterintui-
tive that arsenate, which is not very toxic, should be converted
to the much more toxic arsenite prior to transport out of the
cytosol. Why are there no arsenate-speci¢c e¥ux systems? We
speculate that this is a accident of evolution. Since the pri-
mordial atmosphere was not oxidizing, most arsenic would
have been in the form of As(III), and early organisms would
have evolved detoxi¢cation mechanisms to cope with As(III),
not As(V). Once the atmosphere became oxidizing, arsenite in
oceans and other surface waters would have been oxidized to
arsenate. Thus mechanisms to cope with As(V) evolved to use
existing arsenite extrusion systems. Since the conversion of a
phosphatase to a reductase is relatively easy to accomplish in
the laboratory, its evolution during the formation of an oxy-
genic world would have been rapid.
4. Prokaryotic arsenic extrusion systems
In bacteria there are two basic mechanisms of arsenite ex-
trusion. One is carrier-mediated e¥ux via an arsenite carrier
protein, where energy is supplied by the membrane potential
of the cell, and the other by an arsenite-translocating ATPase
[36]. Two unrelated families of arsenite carriers have been
identi¢ed (Fig. 2C). An arsenite-resistance membrane protein
was identi¢ed in the SKIN element of B. subtilis, and is found
in some other bacteria, archaea and fungi [37]. However, the
majority of bacteria use ArsB, which is found in most ars
operons, to extrude arsenite. When ArsA is co-expressed
with ArsB, an ArsAB complex is formed that is obligatorily
coupled to ATP. Some bacteria have three-gene arsRBC op-
erons and extrude arsenite by ArsB alone, while others have
¢ve-gene arsRDABC operons and use the ArsAB pump [1]
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(ArsR and ArsD, which are As(III)-responsive repressors of
the ars operons, are not discussed here; for a review, see [38]).
We have speculated that the ¢ve-gene operons arose by in-
sertion of the arsDA genes into a three-gene operon [1].
ArsB is a 429-residue integral membrane protein with 12
membrane-spanning segments [39]. It appears to be a uniport-
er that uses the membrane potential, positive exterior, to ex-
trude arsenite. Even though the pKa of 9.2 favors As(OH)3
over As(OH)2O31, the equilibrium ensures that some anion is
always available to ArsB. E. coli has a chromosomal arsRBC
operon that confers moderate resistance to arsenite. However,
when ArsA is synthesized in E. coli from the plasmid R773
arsRDABC operon, cells are more resistant to arsenite be-
cause the ArsAB ATPase is much more e⁄cient at arsenite
extrusion than ArsB alone [36].
The 583-residue ArsA ATPase is a member of a family of
ATPases that probably arose from GTPases [40]. It is nor-
mally bound to ArsB [41], but, in the absence of ArsB, ArsA
is found in the cytosol and can be puri¢ed as a soluble pro-
tein. ArsA has two halves, A1 and A2, that are connected by
a 25-residue linker [42]. A1 and A2 are homologous to each
other, and each has a consensus nucleotide-binding sequence
(NBS) [43]. Both sequences are required for activity, and con-
siderable e¡ort has been expended to elucidate the role of the
individual sites in arsenite transport (see [44] for a recent
summary). The crystal structure of the enzyme has been de-
termined [45]. Three types of domains can be resolved. First,
there are two nucleotide-binding domains (NBDs). These do-
mains are more than NBSs: the NBDs are folded structures
that both contain residues from both A1 and A2. Second,
there is a single metalloid-binding domain (MBD). This is
an allosteric site at the opposite end of the protein from the
NBDs. The MBD consists of a number of residues including
Cys113, Cys172 and Cys422 [46,47] and His148 and His453
[48]. The MBD binds three Sb(III) or As(III), and ArsA ATP-
ase activity is activated by metalloid. Our working hypothesis
is that the contacts between A1 and A2 are loose in the ab-
sence of metalloid, and the NBDs are not fully functional
(Fig. 3). Binding of metalloid at the MBD acts as a ‘molecular
glue’ that holds the A1 and A2 halves of ArsA in tight contact
with each other. In this form the two NBDs are completed by
contact with residues from both A1 and A2 and are thus fully
activated.
Connecting the single MBD to the two NBDs are signal
transduction domains, one in each half of the protein that
can be recognized by a 12-residue signature sequence (D142T-
APTGHTIRLL and D447TAPTGHTIRLL) [49]. ArsA homo-
logs have been found in every sequenced genome of eubacte-
Fig. 1. Arsenical detoxi¢cation in prokaryotes and eukaryotes. Arsenate (As(V)) is taken up by phosphate transporters, and As(III) is taken up
by aquaglyceroporins (GlpF in E. coli, Fps1p in yeast and Aqp7 and Aqp9 in mammals). In both E. coli and S. cerevisiae, arsenate is reduced
to arsenite by the bacterial ArsC or yeast Acr2p enzymes. In both organism, glutathione and glutaredoxin serve as the source of reducing po-
tential [23,32]. The proteins responsible for arsenate uptake and reduction in mammals have not yet been identi¢ed. In E. coli, arsenite is ex-
truded from the cells by ArsB alone or by the ArsAB ATPase [36]. In yeast Acr3p is a plasma membrane arsenite e¥ux protein, and Ycf1p,
which is a member of the MRP family of the ABC superfamily of drug-resistance pumps, transports As(GS)3 into the vacuole. In mammals
Mrp isoforms pump As(GS)3 out of cells. For example, Mrp2 extrudes As(III) into bile [11].
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ria, archebacteria, fungi, plants and animals (Fig. 2D). How-
ever, the physiological roles of eukaryotic homologs are not
known, although probably unrelated to arsenic resistance [50].
In the ArsA structure these sequence are seen as extended
stretches of residues physically linking the NBDs through
Asp142 and Asp447 at the N-terminal end to the MBD
through His148 and His453. This physical connection between
the domains allows ATP hydrolysis at the NBDs to alter the
a⁄nity for As(III), and, reciprocally, allows metalloid binding
at the MBD to alter the a⁄nity for and rate of hydrolysis of
ATP.
This is most easily observed by the introduction of speci¢c
spectroscopic probes into strategic locations in ArsA (Fig. 4).
The probes that we have used are single tryptophan residues
whose £uorescent properties change in response to nucleotide
binding, hydrolysis and/or conformational changes in do-
mains [49,51^53]. In the crystal structure the two NBDs ap-
pear to be hidden within caverns formed by the interface of
the A1 and A2 halves of ArsA [45]. The tryptophans serve as
lamps that light up the caverns that hide the nucleotides from
our view. The intrinsic £uorescence of Trp148 has allowed
real time monitoring of the conformation of ArsA during
the individual steps of the catalytic cycle and has allowed
modeling of the reaction cycle [54,55]. The results suggest
that the rate-limiting step in the overall reaction in the ab-
sence of metalloid activation is the isomerization of a long-
lived conformation of the enzyme, and that binding of metal-
loid overcomes this rate-limiting step, increasing the rate of
hydrolysis. This is not unlike the E1 to E2 transition of P-type
ATPases, where a conformational change from one state to
the other similarly distinguishes the reaction cycle.
In the crystal structure NBD1 is occluded and has ADP
bound [45]. NBD2 is more open, and ATP can be exchanged
into the site. This gives the appearance of an alternation of
sites, and alternating site mechanisms are found in other
transport ATPases [56,57]. Yet a single crystal structure is
like a single frame of a movie. Whether the two NBDs look
like two cylinders of a reciprocating engine cannot be deter-
mined from viewing one frame. As an alternative, the two
sites could be performing di¡erent functions. There is good
evidence to suggest non-equivalence of the two sites. NBD1
hydrolyzes ATP in the absence of activation while NBD2 does
not [58]. For this reason, basal hydrolysis has been termed
unisite catalysis. In the presence of metalloid, both sites hy-
drolyze ATP and participate in multisite catalysis. We have
used the £uorescence of two single tryptophan residues,
Trp141 and Trp446, to light up either NBD1 or NBD2.
Trp141 is adjacent to NBD1 and to the N-terminal Asp142
of the A1 signature sequences. Trp446 is in the equivalent
position in NBD2, next to Asp447 of the A2 signature se-
quence. The £uorescent properties of these two mutants allow
measurement of the rate of hydrolysis in each site singly. The
£uorescent properties of Trp141 clearly show that NBD1 hy-
drolyzes ATP during unisite catalysis [49]. In contrast, Trp447
£uorescence indicates that NBD2 is catalytically inactive until
metalloid is bound, that is, only under multisite conditions
[51]. Although the two NBDs are not equivalent in all re-
spects, the existing data cannot yet distinguish between di¡er-
ent functions for the two or alternating sites catalysis. The use
of more such site-directed spectroscopic probes will greatly
enhance our ability to understand the catalytic cycle of this
ion-translocating ATPase.
Fig. 2. Families of arsenic detoxi¢cation proteins. These families are
growing rapidly, so only representative ones are shown to illustrate
the nature of the lineages. The dendograms were made using the
CLUSTAL4 algorithm [67]. A: The aquaporin superfamily. There
are two subfamilies of aquaporins [16]. The true aquaporins such as
AQP1 allow only water through the channel. The aquaglyceroporins
have larger pores and allow uncharged solutes such as glycerol and
urea through. As(OH)3 enters cells by members of this subfamily.
B: Three families of arsenate reductases. Reductases involved in ar-
senate detoxi¢cation have apparently evolved independently at least
three times [20]. One family is typi¢ed by the E. coli plasmid R773
ArsC that utilizes Grx and GSH as reductants. A second family
represented by the S. aureus plasmid pI258 ArsC utilizes thioredoxin
as a reductant and is related to a family of low-molecular-weight
protein phosphotyrosine phosphatases. Acr2p belongs to the super-
family of PTPases that includes the Cdc25a cell cycle phosphatase.
C: Three families of arsenite transporters. The ArsB family of ar-
senite uniporters has been so far identi¢ed only in bacteria [1]. The
Acr3p family was ¢rst identi¢ed in the B. subtilis SKIN element,
but members were subsequently found in yeast and archaea. The
ABC superfamily of solute-translocating ATPases includes the Mrp
family. Members of this family that have been shown to transport
As(GS)3 include the human Mrp1 and Mrp2, yeast Yfc1p and
Leishmania PgpA. D: The ArsA family. The ArsA family is de¢ned
by the signature sequence DTAPTGHTIRLL and is found in mem-
bers of every kingdom [49]. Those involved in arsenic transport
have two ATPase modules, with a duplicated A1^A2 structure [48].
All eukaryotic members thus far identi¢ed have only one ATPase
module, and their physiological functions are not known [50].
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5. Eukaryotic arsenic extrusion systems
Arsenite resistance is conferred by members of the MRP
(multidrug resistance-associated protein) group of the ABC
superfamily of transport ATPases [59] (Fig. 2C), which phys-
iologically catalyze export of GS-conjugates such as leuko-
triene C4 (LTC4) [60]. MRP1-catalyzed export of glutathione
from cells was increased by arsenite, suggesting that MRP1
functions as a As(GS)3 carrier [61]. In the liver MRP2 ex-
trudes arsenic^glutathione complexes into bile and may be a
major route of arsenic detoxi¢cation in humans [11].
MRP homologs have been shown to confer arsenic resis-
tance in eukaryotic microbes. Metalloid-containing drugs are
still the ¢rst line therapy for trypanosomiasis and leishmania-
sis, and clinical resistance is a serious problem in treatment. In
arsenite-resistant strains selected in vitro there is increased
expression of pgpA, which encodes an MRP homolog [62].
We have recently demonstrated that PgpA transports As(GS)3
Fig. 3. Model for allosteric activation of ArsA by As(III). In the absence of As(III) activator, the A1 and A2 halves of ArsA are loosely inter-
acting, with only the A1 NBD exhibiting a basal rate of ATP hydrolysis (unisite catalysis) [51,58]. Binding of Sb(III) or As(III) to the MBD
‘glues’ the two halves of ArsA together, completing the NBDs and accelerating catalysis [49,68].
Fig. 4. Lamps into the caverns of the nucleotides. Single tryptophans introduced into speci¢c locations of ArsA by site-directed mutagenesis
serve as spectroscopic probes of the two NBDs. Three single tryptophan ArsA mutants were constructed containing Trp159 [49,52], Trp141
[49] or Trp446 [51]. Trp141 ‘shines’ directly into NBD1 and shows that NBD1 is active in both unisite and multisite catalysis. The equivalent
residue in A2, Trp446, ‘lights up’ NBD2 and shows that it is not active during unisite catalysis but is during multisite catalysis. Trp159 ‘illumi-
nates’ the MBD and allows the transition from unisite to multisite catalysis to be quanti¢ed [54].
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[63]. In S. cerevisiae an MRP homolog, Ycf1p, has been
shown to confer Cd(II) resistance by pumping Cd(GS)2 into
the vacuole [64,65]. We have demonstrated that Ycf1p also
transports As(GS)3 into the vacuole and confers arsenite re-
sistance in yeast [10]. In addition to Ycf1p, S. cerevisiae has a
gene cluster of three ACR genes that also confer arsenic re-
sistance [28]. Acr1p is a transcription factor, and Acr2p is the
yeast arsenate reductase described above. ACR3 encodes a
membrane protein that is homologous to the B. subtilis
SKIN element arsenite carrier protein and confers arsenite
resistance [10,66]. While Ycf1p is located in the vacuolar
membrane and catalyzes sequestration of As(GS)3 in the vac-
uole, Acr3p is a plasma membrane carrier protein that cata-
lyzes extrusion of arsenite from cytosol. Thus these two sys-
tems are independent of each other and provide parallel
pathways for arsenic detoxi¢cation in yeast. Acr3p homologs
have not yet been found in mammals.
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